重症肌无力病人的胸腺是最初发生自身免疫的器官,尤其是病程短的年轻病人,胸腺切除往往完全缓解,不需免疫抑制治疗。65～80％病人的胸腺炎伴有血管周围间隙和胸腺髓质淋巴滤泡增生(LFH),但一般不累及胸腺皮质。长期应用免疫抑制剂治疗重症肌无力应首选硫唑嘌呤(AZA)。Mertens等认为,长期应用AZA治疗有效,肌无力症状为明显改善,也不需切除胸腺,而用可的松则引起胸腺可逆性萎缩,但AZA是否影响胸腺形态学变化还不清楚。作者再次检查16例重症肌无力病人的非肿瘤性胸腺的标本。这些病例都是先用免疫 Patients with myasthenia gravis are the first to develop autoimmune thymus, especially young patients with short duration of disease, thymus resection often complete remission, without immunosuppressive therapy. Thyritis is associated with perivascular space and thymic medullary lymphatic follicular hyperplasia (LFH) in 65-80% of patients, but generally does not affect the thymic cortex. Long-term use of immunosuppressive agents should be preferred azathioprine (AZA) for the treatment of myasthenia gravis. Mertens, etc., that the long-term treatment with AZA effective, no significant improvement in muscle weakness, no need to remove the thymus, and cortisone caused by reversible atrophy of the thymus, but whether AZA affect thymus morphological changes is unclear. The authors re-examined 16 non-tumorous thymus specimens from patients with myasthenia gravis. These cases are first immunization